NxStage Celebrates Second Annual National Home Hemodialysis Day
Renal industry leader promotes awareness of home hemodialysis during National Kidney Month; Boston's Zakim Bridge is lit green to commemorate Home Hemodialysis Day
LAWRENCE, Mass., March 19, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is proud to celebrate the second annual Home Hemodialysis Day today, March 19, 2015, during National Kidney Month. Observed annually on the third Thursday of March, this initiative is dedicated to raising awareness of home hemodialysis, including nocturnal therapy, with the NxStage® System One™ and empowering dialysis patients to choose a therapy that is right for them. This evening in Boston, the city's iconic Zakim Bridge will be lit green in support of NxStage's awareness efforts and to commemorate Home Hemodialysis Day.
Home Hemodialysis Day provides a platform for home dialyzors and their care partners to share their experiences and stories with others to strengthen the home hemodialysis community. To celebrate the day, NxStage is distributing green ribbons at dialysis centers across the country and highlighting inspiring patient stories at http://ww2.nxstage.com/patient-stories.html. At the same time, the Company is encouraging patients and care partners to unite, spread the word and capture their support using the hashtag, #HomeHemodialysisDay.
"With home nocturnal therapy, I get to live life on my own terms," said Robby Richardson of Savannah, GA who performs more frequent nocturnal therapy at home with the System One. "By doing my treatments while I sleep, I feel better and am able to maintain my full-time job teaching special education to high school students. Nocturnal therapy has worked so well for me that I've also gone back to my passion of leading ghost tours around the historic district in Savannah. Nocturnal therapy has allowed me to make dialysis work for my life, and not the other way around."
"We have made huge strides in advancing access to home hemodialysis care over the years, most recently receiving FDA clearance for the System One as the first and only machine approved for nocturnal therapy," said NxStage President, Joe Turk. "Still, only a tiny fraction of patients that could truly benefit have access today. We are building on the tradition of National Home Hemodialysis Day to empower all of our patients to share their life-changing stories, and help others understand the significant clinical and quality of life benefits that our home hemodialysis therapies can offer."
For more information about the System One, or home nocturnal hemodialysis, please visit www.nxstage.com. To see Robby Richardson's personal account of his experience with home hemodialysis, please visit our YouTube page.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage
Tel: (978) 332-5923
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article